A recent Gastroenterology digest,
as sent to subscribers

Study Type: Preclinical translational research (single-cell RNA-sequencing, proteomics, spatial transcriptomics, and organoid/fibroblast coculture experiments)

Key Question: Which fibroblast-secreted factor drives progression from gastric metaplasia (SPEM) to dysplasia, an early step in gastric carcinogenesis?

Key Findings:

• SPON2 was the most upregulated, selectively secreted protein in metaplasia- and cancer-derived fibroblasts versus normal fibroblasts, with PDGFRA+/SPON2+ fibroblasts localised adjacent to metaplastic glands in human tissue.
• SPON2 knockdown in cancer-derived fibroblasts abolished dysplastic induction in cocultured SPEM organoids, preserving metaplastic identity.
• Recombinant SPON2 induced dysplasia markers and suppressed metaplastic markers in gastroids; this effect was reversible upon SPON2 withdrawal.

Clinical Relevance: SPON2 represents a novel, potentially targetable stromal driver of gastric pre-neoplastic progression, offering a mechanistic biomarker or therapeutic target relevant to UK gastric cancer surveillance and chemoprevention strategies in high-risk metaplasia/atrophic gastritis patients.

Limitations: Findings are based on in vitro organoid–fibroblast coculture models and human tissue correlation, without in vivo validation of causality or clinical outcome data.

Study Type: Preclinical translational study (in vitro and in vivo experimental models)

Key Question: Can CAR T cells engineered against the CA19-9 glycan safely and effectively target pancreatic and other GI cancers?

Key Findings:

• Screening of 14 CAR constructs identified one optimal design (AbLIFT15.28z) with robust T cell expansion and CA19-9-restricted cytotoxicity in PDAC cell lines and patient-derived organoids.
• In immunocompetent murine PDAC models, AbLIFT15.28z CAR T cells produced significant anti-tumour effects against both primary and metastatic disease.
• Efficacy extended to CA19-9-expressing colon, gastric, oesophageal, and biliary tract tumours, with tumour-specific killing sparing antigen-negative cells.

Clinical Relevance: This provides proof-of-concept for a novel cell-surface target in PDAC and other GI malignancies with limited immunotherapy options, supporting future early-phase trials relevant to UK GI oncology and cellular therapy centres.

Limitations: Findings are based solely on preclinical models (cell lines, organoids, murine models) and require validation in human clinical trials before translation.

Study Type: Commentary/conceptual model (non-empirical, hypothesis-generating)

Key Question: Could an "accelerated carcinogenesis" pathway, driven by cumulative environmental/lifestyle exposures, explain rising early-onset CRC and post-colonoscopy CRC that evade conventional precursor-based screening models?

Key Findings:

• Proposes that exposure-driven subclinical inflammation, immune dysregulation, microbiome disruption and epigenetic remodelling can compress the adenoma-to-carcinoma timeline, bypassing or shortening classical precursor stages.
• Introduces "oncoembryonic reprogramming" as a candidate molecular mechanism linking mucosal remodelling to accelerated malignant transformation.
• Frames sporadic microsatellite-stable EOCRC and a subset of PCCRC as sentinel cases of this broader accelerated pathway, rather than isolated phenomena.

Clinical Relevance: For UK gastroenterologists delivering the NHS Bowel Cancer Screening Programme, this model offers a rationale for observed screening/surveillance failures and PCCRC, potentially informing future risk stratification and interval adjustments beyond standard adenoma-based paradigms.

Limitations: This is a theoretical framework without new primary data, so its mechanisms and clinical implications require empirical validation.

Study Type: Translational cohort study (prospective GEM cohort + South Korean nationwide validation) with mechanistic murine modelling.

Key Question: Does childhood, versus adult, exposure to a sibling with Crohn's disease (CD) increase CD risk via gut microbiome alterations?

Key Findings:

• Childhood sibling exposure conferred a fourfold higher CD risk in GEM (aHR 4.00, 95% CI 1.83–8.75), replicated in the Korean cohort (aHR 2.54, 95% CI 1.70–3.81).
• Childhood exposure was linked to reduced Lachnospira, Roseburia and Colidextribacter, partially mediating CD risk; transplanting this microbiota into germ-free mice worsened colitis and raised mucosal IL-22.
• A combined faecal calprotectin/enterotype risk model identified a high-risk subgroup (Blautia- or Prevotella-enriched) with 22.5% 10-year cumulative CD incidence.

Clinical Relevance: Supports targeted surveillance (e.g., FCP and microbiome profiling) for siblings of CD patients exposed in childhood, informing future risk-stratified screening pathways within UK IBD services.

Limitations: Mediation and mechanistic conclusions rely on observational microbiome associations and murine transfer models, limiting direct causal inference in humans.

Study Type: Commentary/editorial (perspective article on risk stratification frameworks)

Key Question: Should clinical management of compensated advanced chronic liver disease shift from HVPG-defined clinically significant portal hypertension (CSPH) towards non-invasive, outcome-based prediction models?

Key Findings:

• CSPH (HVPG ≥10 mmHg) confers markedly higher 4-year decompensation risk than its absence (29% vs 10%)
• Non-invasive tools (elastography-based models, ANTICIPATE, Non-Invasive CSPH Estimated Risk, Portal Hypertension Decompensation Score) show prognostic accuracy comparable to HVPG for predicting decompensation
• NITs enable longitudinal, dynamic reassessment of risk and treatment response, unlike static HVPG thresholds

Clinical Relevance: For UK gastroenterology services, wider adoption of validated NIT-based risk models could reduce reliance on invasive HVPG measurement (limited availability in most NHS centres), enabling more accessible, serial risk stratification and earlier intervention in compensated cirrhosis pathways.

Limitations: As a commentary, it proposes conceptual and terminological reform rather than presenting new comparative outcome data, and calls for standardised endpoint definitions before models can be validated for widespread clinical adoption.

Study Type: Translational proteogenomic/molecular profiling study (cohort-based discovery and preclinical validation)

Key Question: Can integrated proteomic and phosphoproteomic profiling of neuroendocrine carcinomas across tissue types define molecular subtypes with actionable biomarkers and therapeutic targets?

Key Findings:

• Proteomic analysis of 267 NECs from 26 sites confirmed five transcriptional subtypes (ASCL1, NEUROD1, HNF4A, POU2F3, YAP1), each linked to distinct lineage programmes and RB1 status.
• Subtype H (predominantly gastroenteropancreatic NEC) showed selective NAD+ biosynthesis deficiency; NAMPT inhibition induced synthetic lethality with complete tumour regression in vivo.
• Four tumour microenvironment subtypes were identified; an "inflamed" TME signature predicted superior immunotherapy response across tissue origins.

Clinical Relevance: Offers UK gastroenterology and oncology teams a potential framework for subtype-specific biomarker testing and targeted therapy (e.g., NAMPT inhibitors) in gastroenteropancreatic NEC, a group with currently limited treatment options and poor prognosis.

Limitations: Findings are largely derived from tissue/preclinical models with in vivo validation limited to xenografts, requiring prospective clinical validation before practice change.

Study Type: Retrospective international multicentre cohort study (GLOBAL-BTC registry)

Key Question: Does pre-existing chronic liver disease (CLD) influence stage at diagnosis and survival outcomes in cholangiocarcinoma (CCA)?

Key Findings:

• CLD-associated CCA (n=993/3,743) presented at earlier stage (localized 57% vs 43%), better ECOG status, lower CA19.9, and more often intrahepatic subtype (64% vs 42%) versus non-CLD CCA.
• CLD patients underwent curative-intent surgery more frequently (60% vs 48%) and had improved survival (mOS 12.2 vs 11.1 months; HR 0.88, 95% CI 0.80–0.98), most pronounced in intrahepatic CCA (HR 0.77, 95% CI 0.68–0.87).
• Treatment response rates were similar across CLD status, suggesting survival benefit is driven by earlier detection rather than differential treatment efficacy.

Clinical Relevance: Supports strengthening structured HCC-style surveillance pathways for high-risk CLD patients (e.g., cirrhosis, PSC) within NHS hepatology services to enable earlier CCA detection and surgical eligibility.

Limitations: Retrospective design with heterogeneous CLD definitions and surveillance practices across centres limits causal inference regarding the mechanism of earlier detection.

Study Type: Population-based prospective cohort study

Key Question: How do alcohol consumption and cardiometabolic risk factors, separately and jointly, influence 10-year cirrhosis risk?

Key Findings:

• 10-year absolute cirrhosis risk rose steeply with alcohol intake (0.14% at 1–7 drinks/week to 4.6% at >42 drinks/week); alcohol accounted for 59.9% of population attributable risk.
• Obesity, diabetes, hypertension, and smoking each conferred 2–3-fold higher risk, but their impact was only significant at ≤28 drinks/week, becoming non-significant in heavier drinkers; dyslipidaemia showed no independent association.
• Smoking showed supra-additive interaction with alcohol across all consumption levels; obesity, diabetes, and hypertension showed supra-additivity mainly at moderate intake.

Clinical Relevance: Supports prioritising alcohol reduction as the principal cirrhosis prevention strategy in UK practice, with cardiometabolic risk modification and smoking cessation as adjunctive targets, particularly relevant to MetALD classification and NHS liver disease prevention pathways.

Limitations: Self-reported alcohol consumption and cardiometabolic risk factors risk misclassification, potentially underestimating true effect sizes.